News
AKBA
0.9245
+2.79%
0.0251
Akebia announces new Vafseo patent
TipRanks · 3d ago
Akebia Therapeutics Granted New Patent And Listed In Orange Book; Notified Of Eligibility To Extend Expiration Of Composition Of Matter Patent Covering Vafseo
Benzinga · 3d ago
Akebia says new Vafseo dosing patent is listed in FDA Orange Book
PUBT · 3d ago
Weekly Report: what happened at AKBA last week (0601-0605)?
Weekly Report · 5d ago
Akebia Therapeutics grants new hire options for 8,400 shares at $1.02 each
PUBT · 06/01 20:07
AKEBIA THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 06/01 20:05
Weekly Report: what happened at AKBA last week (0525-0529)?
Weekly Report · 06/01 09:48
Q32 Bio: "Buy" On Bempikibart Advancement And Mid-2026 Data Catalysts
Seeking Alpha · 05/28 13:18
Akebia Therapeutics presents at Jefferies Global Healthcare Conference
PUBT · 05/28 12:05
Weekly Report: what happened at AKBA last week (0518-0522)?
Weekly Report · 05/25 09:50
Akebia Therapeutics Earnings Call: Vafseo Drives Transition
TipRanks · 05/20 04:48
Weekly Report: what happened at AKBA last week (0511-0515)?
Weekly Report · 05/18 09:50
Weekly Report: what happened at AKBA last week (0504-0508)?
Weekly Report · 05/11 09:48
Akebia Therapeutics Balances Vafseo Momentum With Headwinds
TipRanks · 05/09 01:21
Akebia outlines Phase II FSGS study of up to ~60 patients as Vafseo reaches nearly 7,500 patients
Seeking Alpha · 05/07 19:52
Akebia plunges 20% on muted Q1 print
Seeking Alpha · 05/07 16:35
Akebia reports Q1 EPS (3c), consensus 0c
TipRanks · 05/07 15:21
Akebia GAAP EPS of -$0.03 in-line, revenue of $53.5M beats by $1.83M
Seeking Alpha · 05/07 11:14
Akebia Q1 revenue falls, net income misses analyst estimates on higher expenses
Reuters · 05/07 11:11
Akebia Q1 FY26 turns to net loss of $9.1 million; revenue falls to $53.5 million
PUBT · 05/07 11:10
More
Webull provides a variety of real-time AKBA stock news. You can receive the latest news about Akebia Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About AKBA
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). The Company's development pipeline includes mid-stage rare kidney disease pipeline assets (praliciguat and AKB-097) and early-stage pipeline assets (AKB-9090 and AKB-10108), which are HIF molecules.